Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8693173 | 0.83 | AKR1B1 (0.49) | AKR1B1KMT2ASMN1; SMN2NPC1MAPT | |
| SCHEMBL14601731 | 0.82 | ALDH1A1 (0.48) | AKR1B1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL5598431 | 0.79 | AKR1B1 (0.43) | AKR1B1KMT2AKDM4ES1PR5RXFP1 | |
| SCHEMBL7638364 | 0.79 | AKR1B1 (0.45) | AKR1B1KMT2AKDM4ES1PR5RXFP1 | |
| SCHEMBL14458213 | 0.75 | ALDH1A1 (0.44) | AKR1B1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL14601735 | 0.75 | KDM4E (0.55) | AKR1B1KDM4ERXFP1MAPTPSEN1 | |
| SCHEMBL1272047 | 0.72 | AKR1B1 (0.45) | AKR1B1KMT2AKDM4EADRA2BSMN1; SMN2 | |
| SCHEMBL8698751 | 0.72 | AKR1B1 (0.47) | AKR1B1KMT2AKDM4EADRA2BSMN1; SMN2 | |
| SCHEMBL28336689 | 0.72 | TSHR (0.62) | SMN1; SMN2MAPT | |
| SCHEMBL271796 | 0.71 | AKR1B1 (0.44) | AKR1B1KMT2AKDM4ERXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7060851-B2 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2005-06-16 | — | — | US | disclosed |
| CN-1623977-A | Method of preparing retroviral protease inhibitor intermediates | SEARLE & CO (US) | 2005-06-08 | — | — | CN | disclosed |
| US-6849760-B2 | Method of preparing retroviral protease inhibitor intermediates | G. D. SEARLE & CO. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. | 2003-09-11 | — | — | US | disclosed |
| US-6515162-B2 | Precipitating or crystallizing a salt from solution; suitable as intermediates for large scale production of enzyme inhibitors, e.g. hydroxyethylamine, hydroxyethylurea and hydroxyethylsulfonamide | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| US-20010047111-A1 | Method of preparing retroviral protease inhibitor intermediates | NG JOHN S (US) | 2001-11-29 | — | — | US | disclosed |
| EP-0804410-B1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | SEARLE & CO (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6201150-B1 | DIASTEREOMER PURIFICATION METHOD COMPRISING PREPARING AN ORGANIC ACID OR INORGANIC ACID SALT OF AN AMINO COMPOUND AND PRECIPITATING OR CRYSTALLIZING SAID SALT FROM A SOLUTION | G.D. SEARLE & CO. | 2001-03-13 | — | — | US | disclosed |
| US-5831117-A | ACID SALTS | G. D. SEARLE & CO. (US) | 1998-11-03 | — | — | US | disclosed |
| CN-1177955-A | Process for preparing retroviral protease inhibitor intermediates | SEARLE & CO (US) | 1998-04-01 | — | — | CN | disclosed |
| EP-0804410-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022275-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | ACE, REN, MME | AKR1B1 1846/4885KMT2A 1425/4885KDM4E 1543/4885 |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | AKR1B1 1771/4885KMT2A 1342/4885KDM4E 1570/4885 |
| US-20010047111-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | AKR1B1 1771/4885KMT2A 1342/4885KDM4E 1570/4885 |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | AKR1B1 1693/4885KMT2A 1286/4885KDM4E 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.